[February 25, 2011 Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the February 16, 2011 comment letter (the “Comment Letter”) to Mr. Ronghua]
[February 25, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the February 16, 2011mment letter (themment Letter) to Mr. Ronghua]
[February 25, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the February 16, 2011mment letter (themment Letter) to Mr. Ronghua]
[] [Biostar Pharmaceuticals to Host Virtual Presentation February 18th at 10:30 AM EST XIANYANG, China, Feb. 17, 2011 -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang, PRC-based manufacturer of an over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of other pharmaceutical products in the PRC, today announced that Bill Chen, CFO, will host a]
[ex99-1.htm 2 EX-99.1] [Biostar Pharmaceuticals to Host Virtual Presentation February 18th at 10:30 AM EST XIANYANG, China, Feb. 17, 2011 -- Biostar Pharmaceuticals, (Nasdaq: BSPM) ("Biostar" or "thempany"), Xianyang,-based manufacturer of an over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules, and a variety of other pharmaceutical products in the today announced that Bill Chen, CFO, will host a]
[January 13, 2011 Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the December 29, 2010 comment letter (the “Comment Letter”) to Mr. Ronghua]
[January 13, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the December 29, 2010mment letter (themment Letter) to Mr. Ronghua]
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the liabilities of]
